Development of Depression Test Kits and Launch of Research Reagents
First written in FY2016-Q4. 21 of 26 entries say "Restated". Latest entry: FY2024-Q2.
0 other companies' latest entry also says "Restated".
- FY2024-Q2RestatedAnnual report
「Promoted research and development and other initiatives aimed at commercializing mental health biomarkers.」
Continuing research and development aimed at commercializing mental health biomarkers. - FY2024-Q1RestatedAnnual report
「In addition to promoting research and development focused on developing new services for highly sensitive comprehensive analysis and expanding the functional materials development support service, we promoted research and development aimed at commercializing mental health biomarkers.」
Continuing research and development aimed at commercializing mental health biomarkers. - FY2023-Q3RestatedAnnual report
「In research and development, we continued to promote R&D aimed at commercializing biomarkers for major depressive disorder (hereinafter, “depression”) and developing new services in the healthcare solutions business, among other initiatives.」
Continuing research and development aimed at commercializing depression biomarkers. No new stage, such as product launch or completion of commercialization, is described. - FY2023-Q1RestatedAnnual report
「In research and development, we continued to promote R&D aimed at commercializing biomarkers for major depressive disorder (hereinafter, “depression”) and developing new services in the healthcare solutions business.」
Continuing research and development aimed at commercializing depression biomarkers. - FY2022-Q3RestatedAnnual report
「In the healthcare solutions business (formerly the biomarker business), we continued research and development aimed at commercializing biomarkers for major depressive disorder (hereinafter, “depression”), while also considering new pipelines and related businesses.」
Continuing research and development aimed at commercializing depression biomarkers, as well as consideration of new pipelines and related businesses. - FY2022-Q1RestatedAnnual report
「In the healthcare solutions business (formerly the biomarker business), we continued research and development aimed at commercializing biomarkers for major depressive disorder (hereinafter, “depression”), while also considering new pipelines and related businesses.」
For the former biomarker business, continuing research and development aimed at commercializing depression biomarkers, as well as consideration of new pipelines and related businesses. - FY2021RestatedAnnual report
「In the biomarker business, we continued research and development aimed at commercializing biomarkers for major depressive disorder (hereinafter, “depression”), while also continuing to work on new business development and other initiatives.」
Continuing research and development aimed at commercializing depression biomarkers and developing new businesses. - FY2021-Q3RestatedAnnual report
「In the biomarker business, we continued research and development aimed at commercializing biomarkers for major depressive disorder (hereinafter, “depression”), while also considering new pipelines and related businesses.」
Continuing research and development aimed at commercializing depression biomarkers, as well as consideration of new pipelines and related businesses. - FY2021-Q2RestatedAnnual report
「In the biomarker business, we continued research and development aimed at commercializing biomarkers for major depressive disorder (hereinafter, “depression”), while also continuing to consider new pipelines and related businesses.」
Continuing research and development aimed at commercializing depression biomarkers, as well as consideration of new pipelines and related businesses. - FY2021-Q1RestatedAnnual report
「In the biomarker business, we continued research and development aimed at commercializing biomarkers for major depressive disorder (hereinafter, “depression”), while also continuing to consider new pipelines and related businesses.」
Continuing research and development aimed at commercializing depression biomarkers, as well as consideration of new pipelines and related businesses. - FY2020RestatedAnnual report
「In the biomarker business, we continued research and development aimed at commercializing biomarkers for major depressive disorder (hereinafter, “depression”), while also considering new pipelines and related businesses.」
Continuing research and development aimed at commercializing depression biomarkers, as well as consideration of new pipelines and related businesses. - FY2020-Q3RestatedAnnual report
「In the biomarker business, we continued research and development aimed at commercializing biomarkers for major depressive disorder (hereinafter, “depression”), while also considering new pipelines and related businesses.」
Continuing research and development aimed at commercializing depression biomarkers, as well as consideration of new pipelines and related businesses. - FY2020-Q2RestatedAnnual report
「In the biomarker business, we continued research and development aimed at commercializing biomarkers for major depressive disorder (hereinafter, “depression”), while also considering new pipelines and related businesses.」
Continuing research and development aimed at commercializing depression biomarkers, as well as consideration of new pipelines and related businesses. - FY2020-Q1RestatedAnnual report
「In the biomarker business, we continued research and development aimed at commercializing biomarkers for major depressive disorder (hereinafter, “depression”), while also considering new pipelines and related businesses.」
Continuing research and development aimed at commercializing depression biomarkers, as well as consideration of new pipelines and related businesses. - FY2019RestatedAnnual report
「In the biomarker business, we continued to promote the practical application and commercialization of PEA (a depression biomarker), while working to create new pipelines, mainly in the mental health field.」
Continuing the practical application and commercialization of PEA and the creation of new pipelines. - FY2019-Q3RestatedAnnual report
「In the biomarker business, we continued technology development and organizational preparations aimed at commercializing biomarkers for major depressive disorder (hereinafter, “depression”), while also considering new pipelines and related businesses.」
Continuing technology development and organizational preparations aimed at commercializing depression biomarkers. - FY2019-Q2RestatedAnnual report
「In the biomarker business, we continued technology development and organizational preparations aimed at commercializing biomarkers for major depressive disorder (hereinafter, “depression”), while also considering new pipelines and related businesses.」
Continuing technology development and organizational preparations aimed at commercializing depression biomarkers. - FY2019-Q1RestatedAnnual report
「In the biomarker business, we continued technology development and organizational preparations aimed at commercializing biomarkers for major depressive disorder (hereinafter, “depression”), while also considering new pipelines and related businesses.」
Continuing technology development and organizational preparations aimed at commercializing depression biomarkers. - FY2018-Q4AdvancedAnnual report
「In this business segment, the company continued efforts in technology development and clinical research aimed at commercializing and developing the depression biomarker business.」
Continuing technology development and clinical research aimed at the practical application and commercialization of depression biomarkers. - FY2018-Q2AdvancedAnnual report
「In this business segment, to commercialize and develop the depression biomarker business, the company continued evaluating the performance of the research-use reagent kit, establishing a supply structure, and developing measuring equipment and other items. It also began a feasibility study in preparation for clinical trials using the depression biomarker and worked on preparations to launch a study group.」
The company continued evaluating the performance of the research-use reagent kit, establishing a supply structure and developing measuring equipment, and reported the start of a feasibility study for clinical trials and preparations to launch a study group. - FY2018-Q1RestatedAnnual report
「In this business segment, to commercialize and develop the depression biomarker business, the company continued research and development of the reagent’s performance evaluation and measuring equipment, with the launch of sales of the research-use reagent kit in mind.」
Performance evaluation of the reagent and research and development of measuring equipment and other items are continuing with the launch of sales of the research-use reagent kit in mind. - FY2017-Q4RestatedAnnual report
「In this business segment, to commercialize and develop the depression biomarker business, the company continued research and development of the reagent’s performance evaluation and measuring equipment, with the launch of sales of the research-use reagent kit in mind.」
Performance evaluation of the reagent and research and development of measuring equipment and other items are continuing with the launch of sales of the research-use reagent kit in mind. Completion of the sales launch is not reported. - FY2017AdvancedAnnual report
「A new subsidiary, HMT-B, was established, and with its launch the company began full-scale investment in product development, clinical development and other activities aimed at commercializing and developing biomarkers for major depressive disorder.」
The company reported the start of full-scale investment in product development and clinical development for depression biomarkers in connection with the launch of HMT-B. - FY2017-Q2AdvancedAnnual report
「In this business segment, to commercialize and develop the depression biomarker business, the company advanced development of a depression test kit, began providing a beta version of a research-use reagent kit in November 2016, and proceeded with field testing, meaning verification of its usefulness by a third-party organization, in preparation for the launch of sales of the reagent kit.」
Provision of the beta version of the research-use reagent kit began in November 2016, and field testing for the start of sales is also under way. This represents progress at a specific development stage, rather than completion of the target. - FY2017-Q1RestatedAnnual report
「To commercialize and develop the depression biomarker business, the company advanced development of a depression test kit with the launch of research-use-only (RUO) reagents during the current fiscal year in mind.」
Development of the depression test kit is continuing with the launch of RUO reagents during the current fiscal year in mind, but completion of the launch is not reported. - FY2016-Q4First statedAnnual report
「To commercialize and develop the depression biomarker business, the company advanced development of a depression test kit with the launch of research-use-only (RUO) reagents during the current fiscal year in mind.」
Development of the depression test kit is progressing with the launch of RUO reagents during the current fiscal year in mind.